Goserelin acetate (Zoladex) plus endometrial ablation for dysfunctional uterine bleeding: a large randomized, double-blind study.

Donnez J, Vilos G, Gannon MJ, Stampe-Sorensen S, Klinte I, Miller RM

Fertility and sterility1 Jul 1997Cited by 20 (Europe PMC)

PMID9207580DOI10.1016/s0015-0282(97)81471-9PepBankPUB-09207580

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In premenopausal women, goserelin increased postoperative amenorrhea versus placebo, 40% versus 26% at 24 weeks.
In plain wordsGoserelin increased amenorrhea versus placebo after endometrial ablation.
Peptide
Goserelin
Outcome
IncreaseAmenorrhea
Study
n: not reported in source
Comparator
Placebo before endometrial ablation
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · 2 monthsAs given in this study (human).
Measurements
Amenorrhea at 24 weeks after surgery
40%
goserelin
Amenorrhea at 24 weeks after surgery
26%
placebo
Source sentences
Summary
At 24 weeks after surgery, significantly more goserelin than placebo patients experienced amenorrhea (40% versus 26%).
1 context sentence(design, population, supporting numbers)
Summary · context
Multicenter, prospective, randomized, double-blind study.Patient(s)Cycling premenopausal women with dysfunctional uterine bleeding.TreatmentPatients were randomized to goserelin or placebo (sham depot) once monthly for 2 months prior to endometrial ablation.
Report a problemFND-0920758001
02HumanRandomized controlled trialEfficacy outcome
In premenopausal women after ablation, blood loss decreased from baseline in both groups but did not differ between goserelin and placebo.
In plain wordsBlood loss after goserelin did not differ from placebo after ablation.
Peptide
Goserelin
Outcome
No significant changeBlood loss
Study
n: not reported in source
Comparator
Placebo before endometrial ablation
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · 2 monthsAs given in this study (human).
Source sentences
Summary
Blood loss was reduced from baseline, but not different between the groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Multicenter, prospective, randomized, double-blind study.Patient(s)Cycling premenopausal women with dysfunctional uterine bleeding.TreatmentPatients were randomized to goserelin or placebo (sham depot) once monthly for 2 months prior to endometrial ablation.
Report a problemFND-0920758002
03HumanRandomized controlled trialEfficacy outcome
In premenopausal women, endometrial thickness at surgery was 1.6 mm with goserelin versus 3.4 mm with placebo.
In plain wordsGoserelin produced a thinner endometrium than placebo at surgery.
Peptide
Goserelin
Outcome
DecreaseEndometrial thickness
Study
n: not reported in source
Comparator
Placebo before endometrial ablation
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · 2 monthsAs given in this study (human).
Measurements
Mean endometrial thickness at surgery
1.6 mm
goserelin
Mean endometrial thickness at surgery
3.4 mm
placebo
Source sentences
Summary
At surgery, mean endometrial thickness was 1.6 mm and 3.4 mm for the goserelin and placebo groups, respectively, with significantly more atrophic glands and stroma in the goserelin group.
1 context sentence(design, population, supporting numbers)
Summary · context
Multicenter, prospective, randomized, double-blind study.Patient(s)Cycling premenopausal women with dysfunctional uterine bleeding.TreatmentPatients were randomized to goserelin or placebo (sham depot) once monthly for 2 months prior to endometrial ablation.
Report a problemFND-0920758003
04HumanRandomized controlled trialEfficacy outcome
In premenopausal women, goserelin increased atrophic glands and stroma versus placebo at surgery.
In plain wordsGoserelin increased atrophic glands and stroma versus placebo.
Peptide
Goserelin
Outcome
IncreaseAtrophic glands and stroma
Study
n: not reported in source
Comparator
Placebo before endometrial ablation
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · 2 monthsAs given in this study (human).
Source sentences
Summary
At surgery, mean endometrial thickness was 1.6 mm and 3.4 mm for the goserelin and placebo groups, respectively, with significantly more atrophic glands and stroma in the goserelin group.
1 context sentence(design, population, supporting numbers)
Summary · context
Multicenter, prospective, randomized, double-blind study.Patient(s)Cycling premenopausal women with dysfunctional uterine bleeding.TreatmentPatients were randomized to goserelin or placebo (sham depot) once monthly for 2 months prior to endometrial ablation.
Report a problemFND-0920758004
05HumanRandomized controlled trialEfficacy outcome
In premenopausal women, surgery was 22% shorter after goserelin than placebo.
In plain wordsSurgery was 22% shorter after goserelin than placebo.
Peptide
Goserelin
Outcome
DecreaseSurgery duration
Study
n: not reported in source
Comparator
Placebo before endometrial ablation
Outcome group
Surgical outcomes · Reproductive and sexual health
Studied dose
Dose not stated · 2 monthsAs given in this study (human).
Measurements
Surgery duration reduction
22 % shorter
goserelin versus placebo
Source sentences
Summary
Surgery was significantly shorter (by 22%) and easier in the goserelin than in the placebo group, with a significantly lower median fluid absorption in the goserelin groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Multicenter, prospective, randomized, double-blind study.Patient(s)Cycling premenopausal women with dysfunctional uterine bleeding.TreatmentPatients were randomized to goserelin or placebo (sham depot) once monthly for 2 months prior to endometrial ablation.
Report a problemFND-0920758005
06HumanRandomized controlled trialEfficacy outcome
In premenopausal women, surgery was easier after goserelin than placebo.
In plain wordsSurgery was easier after goserelin than placebo.
Peptide
Goserelin
Outcome
DecreaseSurgical difficulty
Study
n: not reported in source
Comparator
Placebo before endometrial ablation
Outcome group
Surgical outcomes · Reproductive and sexual health
Studied dose
Dose not stated · 2 monthsAs given in this study (human).
Source sentences
Summary
Surgery was significantly shorter (by 22%) and easier in the goserelin than in the placebo group, with a significantly lower median fluid absorption in the goserelin groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Multicenter, prospective, randomized, double-blind study.Patient(s)Cycling premenopausal women with dysfunctional uterine bleeding.TreatmentPatients were randomized to goserelin or placebo (sham depot) once monthly for 2 months prior to endometrial ablation.
Report a problemFND-0920758006
07HumanRandomized controlled trialEfficacy outcome
In premenopausal women, median surgical fluid absorption was lower after goserelin than placebo.
In plain wordsSurgical fluid absorption was lower after goserelin than placebo.
Peptide
Goserelin
Outcome
DecreaseFluid absorption
Study
n: not reported in source
Comparator
Placebo before endometrial ablation
Outcome group
Surgical outcomes · Reproductive and sexual health
Studied dose
Dose not stated · 2 monthsAs given in this study (human).
Source sentences
Summary
Surgery was significantly shorter (by 22%) and easier in the goserelin than in the placebo group, with a significantly lower median fluid absorption in the goserelin groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Multicenter, prospective, randomized, double-blind study.Patient(s)Cycling premenopausal women with dysfunctional uterine bleeding.TreatmentPatients were randomized to goserelin or placebo (sham depot) once monthly for 2 months prior to endometrial ablation.
Report a problemFND-0920758007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.